| Stage | BAH | % of rev | ASTH | % of rev | Gap · A − B |
|---|---|---|---|---|---|
| Revenue | $2.8B | 100.00% | $973M | 100.00% | BAH ×2.86 |
| Gross profit | $1.4B | 52.02% | $104M | 10.70% | BAH +41.3pp |
| Operating income | $245M | 8.82% | $34M | 3.53% | BAH +5.3pp |
| Pre-tax income | $199M | 7.16% | $27M | 2.80% | BAH +4.4pp |
| Net income | $181M | 6.52% | $18M | 1.90% | BAH +4.6pp |
| Stage | BAH | ASTH | Gap · A − B |
|---|---|---|---|
| Revenue | $2.8B100.00% | $973M100.00% | BAH ×2.86 |
| Gross profit | 52.02%$1.4B | 10.70%$104M | BAH +41.3pp |
| Operating income | 8.82%$245M | 3.53%$34M | BAH +5.3pp |
| Pre-tax income | 7.16%$199M | 2.80%$27M | BAH +4.4pp |
| Net income |
| 6.52%$181M |
| 1.90%$18M |
| BAH +4.6pp |
No disclosed counterparties: ASTH.
None